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Chapter 1 Introduction
INTRODUCTION
Bronchopneumonia remains a common and serious illness, in spite of the
availability of potent new antimicrobials and effective vaccines. In world pneumonia
is  the  sixth  leading  cause  of  death,  and  the  number  one  cause  of  death  from
infectious  diseases  because  pneumonia  is  not  a  reportable  illness,  Pneumonia  is
increasingly being recognized amongpediatric and geriatric patients and those with
co morbidity Such illnesses include chronic obstructive pulmonary disease,  renal
insufficiency,  congestive  heart  failure,  diabetes  mellitus,  coronary artery disease,
malignancy, chronic neurologic disease, and chronic liver disease. The patients may
become infected  with a  variety of  newly identified,  or  previously unrecognized,
pathogens. At the same time, a number of new antimicrobial agents have become
available, some with utility for bronchopneumonia. Paralleling the improvement in
our  antibiotic  armamentarium  has  been  the  evolution  of  bacterial  resistance
mechanisms.
EPIDEMIOLOGY
Pneumonia is a common illness affecting approximately 450 million people a
year and occurring in all parts of the world.pneumonia is not a reportable illness,
Pneumonia is increasingly being recognized among pediatric and geriatric patients
and those with co morbidity Bronchopneumonia  remains  a  common and serious
illness,  in  spite  of  the  availability  of  potent  new  antimicrobials  and  effective
vaccines. In world pneumonia is the sixth leading cause of death, and the number
one cause of death from infectious diseases because Such illnesses include chronic
obstructive pulmonary disease, renal insufficiency, congestive heart failure, diabetes
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mellitus,  coronary  artery  disease,  malignancy,  chronic  neurologic  disease,  and
chronic liver disease.  The patients may become infected with a variety of newly
identified, or previously unrecognized, pathogens. At the same time, a number of
new antimicrobial agents have become available, (Kollef, M. H,et al., 1998)
Health  Organization estimates  that  one  in  three  newborn  infant deaths  is  due to
pneumonia. Approximately half of these deaths can be prevented, as they are caused
by the  bacteria  for  which  an  effective  vaccine  is  available.In  2008,  pneumonia
occurred  in  approximately  156  million  children  (151  million  in  the  developing
countries and 5 million in the developed countries). In 2010it resulted in 1.3 million
deaths, or 18% of all deaths in those under five years, of which 95% occurred in the
developing countries. Countries with the greatest burden of disease include: India
(464illion), income countries China (21 million) and Pakistan (10 Countries with the
greatest  burden  of  disease  include:  India  (464illion),  income countriesChina  (21
million) and Pakistan (10 million). It is the leading cause of death among children in
low.  Many  of  these  deaths  occur  in  the  newborn  period.  The  World  Health
Organization estimates that one in three newborn infant deaths is due to pneumonia.
Approximately half of  these deaths can be prevented,  as  they are caused by the
bacteria for which an effective vaccine is available.
DEFINITION OF BRONCHOPNEUMONIA
Bronchopneumonia can be explained as a clinical  condition of respiratory
tract,  which  connected  with  the  lungs.  It  commonly  refers  to  people  who  had
pneumonia and whose situation wasn’t so bad and they have been treated at home
itself .However in the progress of the illness bronchopneumonia should be treated in
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hospital. (Luna, C. M,et al.,1997) .It affects millions of people every year all over
the world and especially in the developing countries 
HISTORY OF BRONCHOPNEUMONIA 
and it reflected the extent of medical knowledge through the Middle Ages into the
19th century.( Mandell, L. A,et al.,2003).
Symptoms  that  are  more  accurate  was  given  by  Moses  ben-Maimon,  a
Jewish  philosopher  and  physician.  He  was  born  in  1135  in  Spain.  Most  of  his
famous works are based on the Jewish law and ethics. However, Moses ben-maimon
wrote ten medical works originally in Arabic, which was later translated to Hebrew
and English. In these works, he gave a much more precise description of pneumonia,
which is For the study I have collected 462 bronchopneumonia prescription, and
dates  from  two  hospitals.After  collecting  prescription  to  check  the  prescription
according  to  standard  guideline.   From  the  prescription  I  separated  patents
demographics data such as gander wise distribution, alcoholic distribution, smoking
wise distribution ,age wise distribution ,hospital wise distribution and anti microbial
prescription  wise  distribution  data’s.  From  the  prescription  I  collected  patients
medical  cost,  and  separately  oral  cost  injections  rate,  evoheller  cost  and  total
medical cost. Also collected non medical cost such as laboratory tests cost ,nursing
cost ,travelling cost  ,in case of inpatient I collected hospital room cost  also then
prepared non medical cost of each and every patients and recorded it .I collected
total  medical cost of bronchopneumonia from additions of both medical and non
medical cost. Bronchopneumonia is one the infectious disease and I find number of
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days of medical treatement, and average of prescription per day. Finally differentiate
type of antibiotics prescribed for the patient’s ant its total.
 technically similar to the modern definitions of the disease
. 
In  1875,  Edwin  Klebs,  a  German-Swiss  pathologist,  first  observed  the
bacteria in the airways of patients who died due to pneumonia, which was later used
to  discover  the  culprit  of  the  disease.  He  was  born  on  February  6th,  1834  in
Switzerland. He attended the University of Würzburg and later received his PhD
from the University of Berlin. He completed his residency from the University of
Konigsberg. He served as the professor of pathology and taught at various medical
universities  including  in  Switzerland,  Würzburg,  Prague,  Zürich  and  the  United
States.  He also served as  a  physician for  the Prussian Army during the Franco-
Prussian War. To honor his work, bacterial genus Klebsiella was named after him.
He died on October 23rd, 1913 in Switzerland.(ferriere.s,et al.,2002) The two most
common bacterial causes of pneumonia are Klebsiella pneumonia and Streptococcus
pneumonia, which was identified by Albert Fränkel and Carl Friedländer in the year
of 1882.
Sir William Osler, known as  medicinethe father of modern,appreciated the
death and disability caused by pneumonia, describing it as the "captain of the men of
death" in 1645as it had find out sis which was one of the leading causes of death in
that time. This phrase was originally coined byJohn Bunyan in reference to usage of
o  described  pneumonia  as  "the  old  man's  friend"  as  death  was  often  quick  and
painless when there were slower more painful ways to die.
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Lot of findingsn the 180s improved the result  with pneumonia. With the
advent of cephalosphorins andics, modern science ues, In 21ste care in the century,
mortality  from  pneumonia,  dropped  precipitously  by  30%  in  the  developed
countries. Vaccination of infants against neumonia  type B began in 1988 and led to
a  dramatic  decline  in  cases  shortly  thereafter.  Vaccination  against  Streptococcus
pneumoniae in adults and children  and in children in 2100, resulting in a similar
decline. (ferriere.s,et al.,2002)
COMMON SYMPTOMS OF PNEUMONIA
The firstIrrespective of the severity and causative organism the difficulty in
breathing symptom is commonly observed and foremost symptoms associated with
the pneumonia are the difficulty in breathing. The intensity of the pain in breathing
directly related to the intensity of infection Irrespective of the severity and causative
organism  the  difficulty  in  breathing  symptom  is  commonly  observed  with  all
pneumonia patients. The intensity of the pain in breathing directly related to the
intensity of infection. (Ibrahim e h,et al.,2000)
In not only this ther typical symptoms of pneumonia are fever, cough, cold,
felling tierdness time muscular pains.  the fever and cold is a common symptoms to
every diseases, in case of pneumonia the fever will persist throughout the period. A
proper medication can avoid all the above inconvenience.
Pneumonia also fes affects the defense system of the body. In pneumonia remains
inside the body for a longtiout it poses a threat to affect the immune system of the
body. In fact if proper medication and care is not being taken in the right time it will
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lead to fatal. Pneumonia iss advised to treat the pneumonia at the early stage so that
the chance of spreading can be abolished.
Pmeumonia   serious illness, in spite of the availability of potent new antimicrobials
and effective vaccines. In world pneumonia is the sixth leading cause of death, and
the number one cause of death from infectious diseases because pneumonia is not a
reportable illness, Pneumonia is increasingly being recognized among pediatric and
geriatric  patients  and  those  with  co  morbidity  Such  illnesses  include  chronic
obstructive pulmonary disease, renal insufficiency, congestive heart failure, diabetes
mellitus,  coronary  artery  disease,  malignancy,  chronic  neurologic  disease,  and
chronic liver disease
It is noteworthy to mention that if the pneumonia seen with a new born baby,
immediate medication should be started without any further delay. As the new born
babies does not have enough resistant and immunity the treatment should be started
with no time. (kumar a. at el.,2006)
When  pneumonia  also  feect  babesdevelop  symptoms  like  vomiting,  high
fever, cold, cough and difficulty in breathing.
It has also been noticed that some of the patent suffering from pneumonia
has reported the complaint of chest pain while breathing deeply. The major cause
behind the chest pain is the accumulation of pus and fluid inside the air alveoli. The
pus and fluid obstruct the path of breathing and it result the pain in chest. (Ibrahim e
h, et al.,2000)
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Courtesy (Adams)
TYPES OF PNEUMONIA 
There are three types of pneumonia they are
1. Community-Acquired Pneumonia
2. Hospital-Acquired Pneumonia
And finally
3. Health Care-Associated Pneumonia
 Community acquired pneumonia
community-acquired  pneumonia  often  present  withdyspnea,  rigors,  and
pleuritic chest pain cough, fever, chills, fatigue, dyspnea, rigors, and pleuritic chest
pain.   a  patient  with  suspected  community-acquired  pneumonia,(luna  c.m  et
al.,1997)  the  physician  should  first  assess  the  need  for  hospitalization  using  a
mortality  prediction  tool,combined  with  clinical  judgment.  Consensus  guidelines
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from  several  organizations  recommend  empiric  therapy  with  macrolides,
fluoroquinolonesh as the Pneumonia dosagex, ,  or azithromycin Patients who are
hospitalized wouldd be switched from injection .anti  biotcs antibiotics after their
symptoms improve, they are afebrile, and they are able to tolerate oral medications.
hospital  pathways  was  important  deviceto  improve  care  and  maximize  cost-
effectiveness  in  in  patient  with  hospita  atera.et  al.,1997)Community-acquired
pneumonia (CAP) is defined as pneumonia not acquired in a hospital or a long-term
care  facility.  Despite  the  availability  of  potent  new antimicrobials  and  effective
vaccines,1  an  estimated  5.6 million  cases  of  CAP occur  annually in  the  United
States.
Typical  pneumonia  usually  is  caused  by  bacteria  such  as  Streptococcus
pneumonia.  Atypical  pneumonia  usually  is  caused  by  the  influenza  virus,
mycoplasma,  chlamydia,  legionella,  adenovirus,  or  other  unidentified
microorganism. The patient’s age is the main differentiating factor between typical
and atypical pneumonia; young adults are more prone to atypical causes, and very
young  and  older  persons  are  more  predisposed  to  typical  causes.(kollet,m.h  et
al.,1998)
Clinical presentation
Pneumonia is an inflammation or infection of the lungs that causes them to
function abnormally. Pneumonia can be classified as typical or atypical, although the
clinical  presentations  are  often  similar.  Several  symptoms  commonly  present  in
patients with pneumonia.
Symptoms
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Common  clinical  symptoms  of  Community-acquired  pneumonia(CAP)
include  cough,  fever,  chills,  fatigue,  dyspnea,  rigors,  and  pleuritic  chest  pain.
Depending on the pathogen, a patient’s cough may be persistent and dry, or it may
produce sputum. Other presentations may include headache and myalgia.(mandell,l
et al.,2003) Certain etiologies, such as legionella, also may produce gastrointestinal
symptoms.
DIAGNOSIS
Physical examination 
Physical examination may reveal dullness to percussion of the chest, crackles
or  rales  on auscultation,  bronchial  breath sounds,  tactile  fremitus,  and egophony
(“E” to “A” changes). The patient also may be tachypneic.  A prospective study7
showed that patients with typical pneumonia were more likely than not to present
with dyspnea and bronchial breath sounds on auscultation.(micek,s .t et al.,2005)
Radiography
Chest radiography (posteroanterior and lateral views) has been shown to be a
critical  component  in  diagnosing pneumonia.8  According  to  the  latest  American
Thoracic Society (ATS) guidelines for the diagnosis and treatment of adults with
community acquired pneumonia,  all  patients  with  suspected community acquired
pneumonia should have a chest radiograph to establish the diagnosis and identify
complications (pleural effusion, multilobar disease).Chest radiography may reveal a
lobar  consolidation,  which  is  common  in  typical  pneumonia,or  it  could  show
bilateral, more diffuse infiltrates than those commonly seen in atypical pneumonia.
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(micek,s .t et al.,2005) However, chest radiography performed early in the course of
the disease could be negative.
Laboratory tests for community-acquired pneumonia
Historically,  common  laboratory  tests  for  pneumonia  have  included
leukocyte count, sputum Gram stain, two sets of blood cultures, and urine antigens.
Laboratory test will given a clear data of current situation and infection condition of
body. However, the validity of these tests has recently been questioned after low
positive culture rates were found (e.g., culture isolates ofS. Pneumonia were present
in only 40 to 50 percent of cases) Such low positive culture rates are likely due to
problems  with  retrieving  samples  from  the  lower  respiratory  tract,  previous
administration  of  antibiotics,  contamination  from  the  upper  airways,  faulty
separation of sputum from saliva when streaking slides or plates, or viral etiology.
(Roubinian t,et al.,2006) Furthermore,  sputum samples are adequate in only 52.3
percent of patients with CAP, and only 44 percent of those assumptions that  the
presenting disease is caused by acommon bacterialpathogens
TREATMENT ALGORITHM FOR COMMUNITY ACQUIRED PNEUMONIA
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This is the treatment algorithm for community acquired pneumonia and its
shows that after pneumonia treatment any co morbidities shows then this classified
to risk class, in this also divided in to two .One is low risk class and moderate and
high  risk  class  In  this  group  of  patients  referred  to  inpatient  and  they  need
intravenous antibiotic treatment like beta fluroquinolones, ,macrolides or lactumase .
(Williams  c  at  el.,2006)The patients  shows  low risk  class  or  not  shows  any co
morbidities  then  the  treat  as  out  patients  and  prescribed  oral  antibiotics  like
macrolides,fluroqunolones, tetracycline’s and penicillin’s  
Hospital acquired pneumonia
Hospital  acquired pneumonia is  defined as  infectin wiil  happend after  48
more after hospital  admission and that was not present at the time of admission.
Ventilator acquired pneumonia is    refers to pneumonia that occurs 48 hours or more
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after endotracheal  intubation. Health care associated pneumonia includes patients
who have  recently  has  been  hosptlize long timess  of  the  infection,  resided  in  a
nursing home or long-term care facil, or received parenteral antimicrobial therapy,
chemotherapy, or wound care within 30 days of pneumonia(abele-horn, et al.,1997)
Pathogenesis
Pneumonia occurs when the host’s ability to fight against invading microbial
pathogens is found in human body.of the immune system could be due to interplay
amongst  different  host  factors,  a  depressed  level  of  consciousness  leading  to
impaired mechanical  (ciliated epithelium and mucus),  humoral,  and cellular  host
including underlying comorbidities,
 inhalation of aerosols containing bacteria, or, less frequently, hematogenous spread
from a distant immunosuppressive medications, and defenses. Bacteria may enter
the  lower  respiratory  tract  by  micro-  or  bolus-aspiration  For  the  study  I  have
collected 462 bronchopneumonia prescription, and dates from two hospitals.After
collecting prescription to  check  the prescription according to  standard guideline.
From the prescription I separated patents demographics data such as gander wise
distribution,  alcoholic  distribution,  smoking  wise  distribution  ,age  wise
distribution  ,hospital  wise  distribution  and  anti  microbial  prescription  wise
distribution  data’s.  From  the  prescription  I  collected  patients  medical  cost,  and
separately  oral  cost  injections  rate,  evoheller  cost  and  total  medical  cost.  Also
collected  non medical  cost  such as  laboratory tests  cost  ,nursing cost  ,travelling
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cost  ,in  case  of  inpatient  I  collected  hospital  room cost  also  then  prepared  non
medical cost of each and every patients and recorded it .I collected total medical cost
of  bronchopneumonia  from  additions  of  both  medical  and  non  medical  cost.
Bronchopneumonia  is  one  the  infectious  disease  and  I  find  number  of  days  of
medical treatement, and average of prescription per day. Finally differentiate type of
antibiotics prescribed for the patient’s ant its total.
of  oropharyngeal  organisms,  inhalation  of  aerosols  containing  bacteria,  or,  less
frequently,  hematogenous  spread  from  a  distant  body  site.micro  aspiration  is
believed to be the most important because of both community-acquired and Hospital
acquired pneumonia. Studies have shown that up to 50% of healthy subjects aspirate
during sleep. Those with abnormal swallowing will be at a higher risk of aspiration.
Hospitalized patients, particularly those who are mechanically ventilated and in a
decreased level of consciousness due to either underlying disease or sedative drugs,
are at the highest risk.(Abele-horn m, et al.,1997).The types of aspirated microbial
pathogens will  depend on the bacterial  colonization of  the oropharynx. Previous
studies demonstrated that about 70% of patients who are hospitalized for at least 4
days will have their oropharynx colonized with gram-negative bacilli  organisms,
rendering GNB as  the most  common pathogen that  causes  HAP.  Gram-negative
bacteria  account  for  fifty  five  percentge  and  60  percetage  of  total  infections  of
pneumonia%.
In mechanically hospitalized tients, incubation during the intubation process,
leakage of colonized oropharyngeal secretions around the endotracheal tube  cuff, or
condensation  of  air  particles  from  a  contaminated  ventilatory  circuit.  Whether
stomach or  sinuses  serve  as  potential  reservoirs  for  bacterial  colonization of  the
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oropharynx  is  still  being  debated.  Theendothelial  ubeper  respiratory  tract  host
defenses allowing for pooling of oropharyngeal secretions above the endotracheal
tube( cuff. In addition, it is believed there is a biofilm formation over the bacterial
colonization of endotracheal tube , making de-colonization of the endotracheal tube
(ET )  difficult.  (Daubar  a,et  al,.1997)  .The  development  ofventilator  asosciated
pneumonia  patientds  mortality  2  to  10  times  higher  than  those  without  hospital
accured pnumonia patients
Causes 
• S  anchopneumonia  mmon  illness.  It  is  caused  by  many different  germs.
Pneumonia that starts in the hospital tends to be more serious than other lung
infections because:
• Pneumonia patinebt pital are often very sick and cannot fight off germs.
• The  types  oeither  posituve  or  gegativeoften  more  dangerous  than  those
outside in the community.
• Pneumonia occurs more often in patients who are using a breathing machine
This machine helps them breathe.
• HAP is also infecte by health care profetionals  and other hospital stafs they
interact  with pneumonia patirnts from one patient to another.  This is why
hand-washing,  wearing  gowns  and  using  other  safety  measures  is  so
important in the hospital.
• Patients is more contact with other patients nia while in the hospital:
Dept.of pharmacy practice 14 JKKMMRF College of pharmacy
Chapter 1 Introduction
• Patients who have drinking ha bit
• persons who underwent chest or cardiac surgeury jor surgery
• peoples they have less innmune systemcancer treatment, certain medicines,
or severe wounds
• Patients have long-term (chronic) lung disease
• Breathe saliva or food into their lungs as a result of not being fully alert or
having swallowing problems
• Patients suffering from chronic obstructive pulmonary diseases
Symptoms
• Fever and chills
• In an elderly person, the first sign of hospital-acquired pneumonia may be
mental changes or confusion
• A cough with greenish or pus-like phlegm (sputum)
• General discomfort, uneasiness, or ill feeling (malaise)
• Loss of appetite
• Nausea and vomiting
• Sharp chest pain that gets worse with deep breathing or coughing
• Shortness of breath
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• Decreased blood pressure and high heart rate
Laboratory test for hospital acquired pneumonia
Tests to check for HAP included
• ABGo measure oxygen levels in the blood
• Blood was culterd by hospital laboratory
• Ct scan and chest x ray from thatthe lungs 
• Blood tyest it meen s compleate blood test
• Test done by pule oximetry                            
• Sputum culture or sputum gram stain, to check for what germs are causing
the pneumonia.
Health care associated pneumonia
Patients also may get bronchopneumonia from other health care profetionals
it may leads to health care associate pneumonia. of pneumonia is called health care-
associated pneumonia.(Alvarez-lerma f,et al.,1996)
OTHER COMMON TYPES OF PNEUMONIA
Types of pneumonia grouped by causes 
Type of pneumonia based on the causing microorganism, they are divided in
to three they are bacterial pneumonia, viral pneumonia, and mycoplasma pneumonia
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Bacterial pneumonia
Bacterial pneumonia can affect anyone at any age. It can develop on its own
or after a serious cold or flu. The most common cause of bacterial pneumonia is
streptococcus  pneumoniae.  Bacterial  pneumonia  can  also  be  caused  by
Chlamydophila  pneumoniaor  legionella  pneumophila.  Pneumocystis  jiroveci
pneumonia is  sometimes seen in those who have weak immune systems, due to
illnesses like AIDS or cancer. (Ambrose p. et al.,)
Viral pneumonia
In most cases, respiratory viruses can cause pneumonia, especially in young
children and the elderly. Pneumonia is usually not serious and lasts a short time.
However, the flu virus can cause viral pneumonia to be severe or fatal. It’s especially
harmful  to  pregnant  women  or  individuals  with  heart  or  lung  issues.  Invading
bacteria can cause complications with viral pneumonia.
Mycoplasma pneumonia
Mycoplasmas are not viruses or bacteria,  but they have traits  common to
both.  They are  the  smallest  agents  of  disease  that  affect  humans.  Mycoplasmas
generally cause mild cases of pneumonia, most often in older children and young
adults.
IDENTIFICATION TESTS FOR BRONCHO PNEUMONIA
Pneumonia can be hard to diagnose because it may seem like a cold or the
flu.  We  may not  realize  it's  more  serious  until  it  lasts  longer  than  these  other
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conditions.Pneumonia was diagnosed based on patient’s medical history, a physical
exam, and test results.
MEDICAL HISTORY
Patient’s signs and symptoms find out by physician and how and when they
began. To find out what type of germ is causing the pneumonia, he or she also may
ask about:
• Any recent traveling done by patient
• Patients hobbies
• Patients exposure to animals
• Patients exposure to sick people at home, school, or work
• Past  and  current  medical  conditions,  and whether  any have  gotten worse
recently
• Any medicinestaken by patient
• Smoking habit of patients
PHYSICAL EXAMINATION TEST FOR PNEUNONIA
Patientslungs are listen physician with the help ofstethoscope. If personson is
suffering from pneumonia , and rumbling sounds when patient inhale. Doctor also
may hear wheezing. Physician may find it hard to hear sounds of breathing in some
areas of your chest. (Alvarez-lerma f,et al.,1996)
Dept.of pharmacy practice 18 JKKMMRF College of pharmacy
Chapter 1 Introduction
DIAGNOSTIC TESTS FOR BRONCHOPNEUMONIA
Chest x ray test for pneumonia
the best test for diagnosing pneumoniawon't tell doctor what kind of germ is causing
the pneumonia..Chest x ray should give a feed back about patient chest and presents
of pneumina infection in the chest area lungs, and blood vessels. A chest x ray is.
However, this test 
(Courtesy:  Adams)
Blood tests for pneumonia
Cbe test will give the information of pathogenisis in patients body present in
the body . including the number of white blood cells in the blood sample .measures
many parts  of   blood,This  test  is  used  to  detect  germs  in  the  bloodstream.  The
number of white blood cells can show whether  have a bacterial infection.
Blood culture test is get information  has spread to patient bloodstream.. A
blood culture is.show which germ caused the infection. physiciant can decide how to
treat the infection.
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Sputum test for pneumonia
this  collected from patient  after  a  deep sputum it  maybbe help to  doctor
what germ is causing pneumonia. Then, he or she can plan treatment.
Chest computed tomograph  for bronchopneumonia
X ray  test  is  the  the  one  of  the  easy method  to  find  out  pneumoniathe
structures  in  patient  chest,  such  as  lungs.Its  show  more  detail  than  those  of  a
standard chest x ray. A chest CT scan is a type of x ray, 
leural fluid culture fro pneumonia test
 this test, a fluid sample is taken from the pleural space its taken between
chest  and  spinal  cavity  of  human  body   physicains  use  a  procedure  called
thoracentesis to collect  the fluid sample. The fluid is studied for germs that may
cause pneumonia.
Pulse oximetry test for pneumonia
If patient very sick, doctor may need to measure the level of oxygen in blood using a
blood sample. The sample is taken from an artery, usually wrist. This test is called an
arterial  blood  gas  test..  Pneumonia can  keep  patient  lungs  from moving enough
oxygen into bloodstream.
For this test, a small sensor is attached to patient finger or ear. The sensor
uses light to estimate how much oxygen is in blood
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Bronchoscopeis a procedure used to look inside the lungs' airways. If patient
is in the hospital and treatment with antibiotics isn't working well, doctor may use
this procedure (Garvey m j,et al.,2002)
Physican   findthin,  flexible  tube  through  patients’ nose  or  mouth,  down
throat, and into the airways. The tube has a light and small camera that allow doctor
to  see  windpipe  and  airways  and  take  pictures.This  are  common  test  for
bronchopneumonia
TRANSMISSION OF PNEMONIA TO PATIENTS TO PATIENTS
The infectiosof  pneumonia is  spredin the mouth and nose of  the infected
person. They can be spread easily to another personthey enter the person's  body
through their mouth, nose, or eyes. When this happens, either through the air or by
touching a contaminated surface. Typically, , a battle begins -- the person's immune
system tries to kill the germs, while the germs try to multiply.
. This is because many of the viruses and bacteria that cause people to get
pneumonia are the same ones that cause upper respiratory infections.  Although a
person with either viral or bacterial pneumonia is contagious, that person's germs are
more likely to cause an upper respiratory infection in another person such as the
common cold andsneezing than pneumonia
TREATEMENT OF BRONCHOPNEUMONIA
General treatment for pneumonia
If the patient has pneumonia, follow by treatment plan, take all medicines as
prescribed,  and  get  ongoing  medical  care.  Ask  to  doctor  when  patient  should
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schedule follow up care.  Doctor may want to have a chest x ray to make sure the
pneumonia is gone.
Although patient may start feeling better after a few days or weeks, fatigue
(tiredness) can persist for up to a month or more.  People who are treated in the
hospital may need at least 3 weeks before they can go back to their normal routines 
Erliar  stage   pneumonia  can  be  treated  noneedthospitalization.  Typically,
bronchodiolator ,antibiotics  , and home care are sufficient for complete resolution.
Howeve r patient with other medical problems, patients pneumonia who are having
trouble  breathing,,  and  the  elderly  may  need  more  advanced  treatment.  ,  the
pneumonia does not improve with home treatment If  the symptoms get worse, or
complications occur, the patientwill often have to be hospitalized. (Garvey m j, et
al.,2002)
Bacterial pneumonia
. Treatment for pneumonia should ideally be based on the causative microorganism
and its known antibiotic sensitivity. The antibiotic choice depends on the nature of
the pneumonia, the most common microorganisms causing pneumonia in the local
geographic  area,  and  the  immune  status  and  underlying  health  of  the
individualAntibiotics  are  used  to  treat  bacterial  pneumonia.  In  contrast,Because
treatment should generally not be delayed in any person with a serious pneumonia,
empiric  treatment  is  usually  started  well  before  laboratory  reports  are  available
antibiotics are not useful for viral pneumonia, although they sometimes are used to
treat  or  prevent  bacterial  infections  that  can  occur  in  lungs  damaged  by a  viral
pneumonia.. However, a specific cause for pneumonia is identified in only 50% of
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people,  even  after  extensive  evaluation..(Antonelli,m.et  al.,1998)  In  the  india  ,
clarithromycin amoxicillin and or erythromycin are the antibiotics selected for most
patients with community-acquired pneumonia;  patients  allergic to penicillin’s are
given erythromycin instead of amoxicillin.doxycycline have displaced amoxicillin
as  first-line  outpatient  treatment  for  community-acquired  pneumonia  India
andAmerica,  where  the  "atypical"  forms  of  CAP  becoming  more  common,
macrolides (such as azithromycin and clarithromycin),  the fluoroquinolones,  and.
The duration  of  treatment  has  traditionally  been  seven  to  ten days,  but  there  is
increasing  evidence  that  shorter  courses  (as  short  as  three  days)  are  sufficient.
(Azouay e, et al.,2006|)
Multiple antibiotics may be administered in combination in an attempt to
treat all of the possible causative microorganisms Antibiotics for HCP first second
-generation cephalosporins, carbapenems, fluoroquinolones, amino glycosides, and
vancomycin.Extremely sick individuals may require intensive care, often including
endotracheal  intubation  and  artificial  ventilation.  .  These  antibiotics  are  usually
given intravenously People who have difficulty breathing due to pneumonia may
require extra oxygen.. Antibiotic choices vary from hospital to hospital because of
regional differences in the most likely microorganisms, and because of differences in
the microorganisms' abilities to resist various antibiotic treatments.
Viral pneumonia
Viral pneumonia caused by influenza A may be treated with rimantadine or
amantadine, while viral pneumonia caused by influenza A or B may be treated with
oseltamivir  orzanamivir.  These  treatments  are  beneficial  only if  they are  started
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within 48 hours of the onset of symptoms. Many strains of H5N1 influenza A, also
known as avian influenza or "bird flu," have shown resistance to rimantadine and
amantadine.  There  are  no  known  effective  treatments  for  viral  pneumonias
causedadenovirus, Hantavirus, or parainfluenza virus by the SARS coronavirus,. .
(Azouay e, et al.,2006|)
Aspiration pneumonia type
A  combination  of  a  beta-lactam  antibiotic  and  metronidazole,  or  an
aminoglycoside.There is no evidence to support the use of antibiotics in chemical
pneumonitis  without  bacterial  infection.  If  infection  is  present  in  aspiration
pneumonia, the choice of antibiotic will depend on several  factors,  including the
suspected  causative  organism  and  whether  pneumonia  was  acquired  in  the
community  or  developed  in  a  hospital  setting.In  cases  where  the  pneumonia
progresses to blood poisoning (bacteremia), just over 20% of sufferers die Common
options include clindamycin, Corticosteroids  are  commonly  used  in  aspiration
pneumonia, but there is no evidence to support their use either. Viral pneumonia may
last  longer,  and  mycoplasma  pneumonia  may take  four  to  six  weeks  to  resolve
completely. .(Azouay e, et al.,2006|).
limited  access  to  x-rays,  limited  antibiotic  choices,  and  inability  to  treat
underlying conditions inevitably leads to higher rates of death from pneumonia. For
these reasons,The mortality rate pneumonia depends on the underlying cause of the
pneumonia.Pneumonia  caused  by  ''Mycoplasma'',''Staphylococcus  aureus''   for
instance, is associated with little mortality. However, about half of the people who
develop methicillin-resistant pneumonia while on a ventilator will die. In regions of
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the  world  without  advanced  health  care  systems,  pneumonia  is  even  deadlier.
Limited access to clinics and hospitals, the majority of deaths in children under five
due to pneumococcal disease occur in developing countries. (Baker a m, et al.,2001)
COMMONLY USED ANTIBIOTICS FOR BRONCHOPNEUMONIA
Macrolides
Generic Name Brand Name
Azithromycin Zithromax, Zmax
Clarithromycin Biaxin
Erythromycin Eryc, EryPed, Ery-Tab
Roxithromycin Biorox,Biolide
The macrolides bind irreversibly to a site on the 50S subunit of the bacterial
ribosome, thus inhibiting the translocation steps of protein synthesis. They may also
interfere  at  other  steps,  such  as transpeptidation.  Generally  considered  to  be
bacteriostatic, they may be bactericidal at higher doses. Their binding site is either
identical or in close proximity to that for clindamycin and chloramphenicol.(Bell r,
et al.,1997)
Tetracyclines
      Generic Name         Brand Name
doxycycline Doryx, Vibramycin
a discussion of the mode of action of tetracyclines requires consideration of
uptake and ribosomal binding mechanisms It is well established that tetracycline’s
inhibit bacterial protein synthesis by preventing the associationTherefore, to interact
with their targets these molecules need to traverse one or more membrane systems
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depending on whether the susceptible organism is gram positive or gram negativ of
aminoacyl-tRNA with the bacterial ribosome. e. Hence,. Also pertinent to this   of
the joint  antibacterial-antiprotozoal activity of the tetracyclines and the microbial
selectivity of the class as a whole. 
(Bergmans  d c,et  al.,1997) Most  of  these  issues  have been considered  at
length in recent years, so the focus here will be on new information.
Fluoroquinolones
commonly  DNA  gyrase  is  more  sensitive  in  gram-negative  bacteria  and
topoisomerase  IV more sensitive in  gram-positive  bacteria  The formation of  the
ternary complex of quinolone, DNA, and either DNA gyrase or topoisomerase IV
occurs through interactions in which quinolone binding appears to induce changes in
both DNA and the topoisomerase that occur separately from the DNA cleavage that
is the hallmark of quinolone. In a given bacterium these 2 enzymes often differ in
their  relative  sensitivities  to  many  quinolones,  and.  Usually  the  more  sensitive
enzyme represents the primary drug target determined by genetic tests, but poorly
understood  exceptions  have  been  documented.actionThe  mode  of  action  of
fluroquinolones  involves  interactions  with  both  DNA  gyrase,  the  originally
recognised  drug  target,  and  topoisomerase  IV,  a  related  type  II  topoisomerase
(Bergmans d c,et al.,1997) 
Generic Name Brand Name
Gemifloxacin Factive 320
Levofloxacin Levaquin
Moxifloxacin Avelox 500
Cprofloxacin Ciproxent
CEPHALOSPORINS
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Cephalosporin’s are grouped into "generations" based on their spectrum of
antimicrobial  activity.  Newer  generation  has  significantly  greater  gram-negative
antimicrobial properties.  Cephalosporin’s are classified in to four group. they are
first  generation    drugs  areCefadroxi,Cephalexin,Cephaloridine,Cephalothin,
Cephapirin,Cefazolinand Cephradine
Second generation cephalosporin’s have more antibacterial activity and More
resistant to beta-lactamase ,the drugs are Cefaclor.Cefoxitin.Cefprozil.Cefuroxime
Third  generation  cephalosporins  have  abroad  spectrum  of  activity  and
increased activity against gram-negative organisms and  excellent activity against
most  strains  of  Streptococcus  pneumoniae.The  drugs  are
Cefdinir,Cefixime,Cefpodoxime,Ceftibuten,Ceftriaxone And Cefotaxime
Fourth generation cephalosporin’s a greater resistance to beta-lactamase than
the third generation cephalosporin’s. It cross blood brain barrier and are effective in
meningitis,  more  active  against  pneumococcal.Activity  against  nosocomial
pathogens  such  as  Enterobacter  and  Acinetobacte.The  drugs
areCefepime,Cefluprenam,Cefozopran,Cefpiromeand and  Cefquinome.
Generic Name Brand Name
Cefaclor  Alclor,Alfaclor
Cefadroxil  Acer,Acidrox
Cefprozil  Refzilo.3 cef fc
Cefuroxime Ceftin
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Cephalexin Keflex
Cephalosporin’s are bactericidal agents and have the same mode of action as
other beta-lactamase antibiotics (such as penicillin’s). All bacterial cells have a cell
wall that protects them. Cephalosporins disrupt the synthesis of the peptidoglycan
layer of bacterial cell walls, which causes the walls to break down and eventually
the bacteria die.
Peptidoglycan is a heteropolymeric component of the cell wall that provides
rigid mechanical  stability.  The final  transpeptidation step in  the synthesis  of  the
peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins
(PBPs). PBPs bind to the D-Ala-D-Ala at the end of muropeptides (peptidoglycan
precursors) to crosslink the Peptidoglycan.(Gaillard j c, et al.,2001)
Cephalosporin’s mimic the structure of the D-Alanine link and bind to the
active site of PBPs, disrupting the cross-linking process. If the peptidoglycan fails to
cross-link the cell wall will lose its strength which results in cell lyses.
Penicillin’s
Generic Name Brand Name
Amoxicillin  Mox. A mox
Amoxicillin with clavulanate Augmentin,Amoxiclave
Ampicillin  Acipillin,Ampidil DS
Piperacillin  Antepar,Avizine
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Ticarcillin with clavulanate Timentin
β-Lactam  antibiotics  work  by  inhibiting  the  formation  of  peptidoglycan
cross-links  in  the  bacterial  cell  wall.In  addition,  the  build-up  of  peptidoglycan
precursors triggers the activation of bacterial cell  wall hydrolases and autolysins,
which further digest the bacteria's existing peptidoglycanGram-positive bacteria are
called protoplasts when they lose their cell wall.
Penicillin shows a synergistic effect with aminoglycosides, since the inhibition of
peptidoglycan synthesis allows aminoglycosides to penetrate the bacterial cell wall more
easily, For the study I have collected 462 bronchopneumonia prescription, and dates
from two hospitals.After collecting prescription to check the prescription according
to standard guideline.  From the prescription I separated patents demographics data
such as gander wise distribution, alcoholic distribution, smoking wise distribution
,age wise distribution ,hospital wise distribution and anti microbial prescription wise
distribution  data’s.  From  the  prescription  I  collected  patients  medical  cost,  and
separately  oral  cost  injections  rate,  evoheller  cost  and  total  medical  cost.  Also
collected  non medical  cost  such as  laboratory tests  cost  ,nursing cost  ,travelling
cost  ,in  case  of  inpatient  I  collected  hospital  room cost  also  then  prepared  non
medical cost of each and every patients and recorded it .I collected total medical cost
of  bronchopneumonia  from  additions  of  both  medical  and  non  medical  cost.
Bronchopneumonia  is  one  the  infectious  disease  and  I  find  number  of  days  of
medical treatement, and average of prescription per day. Finally differentiate type of
antibiotics prescribed for the patient’s ant its total.
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 the  bacteria's  existing  peptidoglycan.  (Gaillard  j  c,  et  al.,2001).  allowing  its
disruption of bacterial protein synthesis within the cell. This results in a lowered  for
susceptible organisms
 DEMOGRAPHIC DATA OF BRONCHOPNEUMONIA
. Pneumonia affects children and families everywhere, but is most prevalent in
asia and africa and europe Pneumonia is  the single largest  cause of  death in
children worldwide Pneumonia is a form of  infection that affects the lungs.which
fill with air when a healthy person breathes. When an individual has pneumonia
The lungs are made up of small sacs called alveoli, , the alveoli are filled with pus
and fluid, which makes breathing painful and limits oxygen intake.
All  theyear  pneumonia  kills  1.1  million  children  under  the  age  of  five  years,
Children  can  be  protected  from  pneumonia,  it  can  be  prevented  with  simple
interventions, and treated with low-cost, low-tech medication and care accounting
for 20% of all deaths of children under sixe years old worldwide. (Faraser, et
at.,2001)
PNEUMONIA IN INDIA
After evidence that India is lagging behind on the Millennium Development
Goal (MDG) of reducing Infant Mortality Rate by 2015, it now turns out that it is
faltering on the child survival MDG as well.(Gupta D, et al.,2012)
The first-ever report tracking global progress against pneumonia, the leading
killer of children under five years of age, finds that India is witnessing the highest
number of pneumonia-related child deaths in the world. The infection is killing 16
lakh children under five every year, more than 3.7 lakh in India alone.
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Commenting on pneumonia deaths among young children in India, president
of the academy informed that the disease globally killed an estimated 1.4 million
children  below  the  age  of  five  years  every  year-more
thanAIDS, malaria and tuberculosis together did. It  is alarming that India accounts
for  almost  25  per  cent  of  the  world's  pneumonia  deaths  of  children. 
Pneumonia accounts for 20 per cent deaths among children below 5 years of age
becoming the leading cause of death in the age group. According to the IAP records,
annually, India witnesses 45 million pneumonia cases among children below 5 years
of which 0.37 million die due to pneumonia,(shah b a, et al.,2010)
PAHRMACIST INVOLVEMENT IN CARE FOR BRONCHOPNEUMONIA
Bronchopneumonia is the most frequently occurring infectious disease in the
world, and it is also the sixth most common cause of death. Pneumonia occurs most
frequently in the winter and in elderly patients. Treatment and prevention strategies
for Pneumonia include antimicrobial therapy targeting the most frequently occurring
causative  microorganism,  as  well  as  smoking  cessation  and  appropriate
immunizations.The  pharmacist,  as  a  part  of  the  health  care  team,  can  assist  in
improving outcomes by optimizing the treatment in patients diagnosed with acute
bronchitis,and pneumonia
ANTIBIOTIC TREATEMENT
Recommendations for cough products should be based upon patient description of
the  cough  as  either  productive  or  nonproductive  Pharmacists  may   play  an
importement role to reduse the pneumonia spreding all over the world.pneumonia
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,Patients  either  seen  in  the  emergency room or  admitted  to  the  hospital  require
counseling for appropriate use of nebulizer or prior to discharge to ensure optimal
therapy.  (Maisha  Kelly Freeman,  et  al.,  2013)as  well  as  selection  of  supportive
therapies  for  cough pharmacist  shoul  council  the  patient  regarding  its   spreding
mode and precoutionse selection and dosing of antibiotic therapy may be guided by
the pharmacist,.. Pharmacists can counsel on appropriate use, adverse effects,
and anticipated outcomes with pharmacotherapy. Also, for those patients who are
admitted  to  the  hospital,  the  pharmacist  is  able  to  recommend  transition  from
intravenous  to  oral  therapies.In  the  community  setting,  pharmacists  play  a
significant role in recommending therapy for cough and no pharmacologic therapies
in patients with pneumonia. in nature.(Bhaskar ,E et al.,2010)
SMOKING CESSATION PROGRAMS CONDUCTED BY PHARMACIST
Pharmacist  play an important  role to  give  information about  bronchopneumonia,
Pharmacist should given the information about wt are the side effects of pneumonia.
Pharmacists and practitioners should assess the smoking status of an individual as
well as their interest in cessation. Further and wt is the relation between smoking
and  pneumonia  etc,  in  case  of  smokers  pneumonia  is  essly  spreded  becouse  of
pneumonia affect the lungs alvioli and in case of smokings it also affect in the lungs
so   pharmacist  must  given  an  information about  pneumonia  ner  for  information
about smoking cessation products since the majority of these are OTC products,
attempts should be made to determine the type of tobacco product being consumed,
as  well  as  how much and  how often.  If  a  patient  is  initially  unwilling  to  stop
smoking, each subsequent visit should assess readiness to quit  as well  as further
education on the benefits of smoking cessation, In case tobaco s of complete and
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long-term abstinence from using any tobacco product.  Other important factors to
discuss with patients, who may or may not be actively using tobacco products, are
the health consequences associated with second-hand and third-hand smoke. In a
clinical setting, patients are able to express how troublesome second-hand smoke is
for their respiratory illness; however, many times a connection with exacerbations
from residual smoke on clothing, furniture, and bedding is not made.(Maisha Kelly
Freeman, et al.,2013)
PRESCRIPTION TREND
This observational study is “to evaluate antimicrobial prescription trend and direct
cost  analysis  of  various  drug  prescribed  for  bronchopneumonia”,  the  study
concludes that patients age wise demographic data shows that 31.2% patients are in
the age group of 31-40 out of  462 patient  144 patients are the above age group
.Gender wise demographic data shows that 292 pneumonia patients are male and
a170 patients are females in my study. Smoking habit distribution data shows that
204 patients are smoker its comes around 44.2% total study population .smokers are
easily  affect  pneumonia  according  to  standard   guidelines   .Anti  microbial
prescription  data  shows  that  100%  patients  are  got  antimicrobial  prescription
because   pneumonia  totally  recovered  from  the  patient   body   by  the  use  of
antimicrobial  administration  .  For  the  theses  work  I  collected  details  from  two
hospitals,  it  shows  267  patients  from   shanker  hospital  and  195  patients  from
ramdas hospital
Cost range of antimicrobial prescription is different in each every patient in
my study shows that 36.9 patients have more than 1000 rupees for antibiotics ,and
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all this patients are inpatients and 37.1% of patients have anti biotic cost range from
2001-400 all this patients are out patients and its 172 patients
Pharmacoeconomics
This observational study is “to evaluate antimicrobial prescription trend and direct
cost  analysis  of  various  drug  prescribed  for  bronchopneumonia”,  the  study
concludes that patients age wise demographic data shows that 31.2% patients are in
the age group of 31-40 out of  462 patient  144 patients are the above age group
.Gender wise demographic data shows that 292 pneumonia patients are male and
a170 patients are females in my study. Smoking habit distribution data shows that
204 patients are smoker its comes around 44.2% total study population .smokers are
easily  affect  pneumonia  according  to  standard   guidelines   .Anti  microbial
prescription  data  shows  that  100%  patients  are  got  antimicrobial  prescription
because   pneumonia  totally  recovered  from  the  patient   body   by  the  use  of
antimicrobial  administration  .  For  the  theses  work  I  collected  details  from  two
hospitals,  it  shows  267  patients  from   shanker  hospital  and  195  patients  from
ramdas hospital
Cost range of antimicrobial prescription is different in each every patient in
my study shows that 36.9 patients have more than 1000 rupees for antibiotics ,and
all this patients are inpatients and 37.1% of patients have anti biotic cost range from
2001-400 all this patients are out patients and its 172 patients
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Orals route of drugs such as antibiotics and other oral drugs are  such as
tablets and syrups cost range vary from patient to patients in my study shows that
294  patients  are  in  the  range  of  401-600  cost  range  its  63.6%  of  total  study
population .
In my study cost range of injections only for out patients not for in patients
because in my study only inpatients are taken injections .it shows that 85 patients are
taken injections in the range of 2001-3000 ,and 25  patients taken in the cost range
of 3001-4000.
Cost range of evoheller is taken in this study it shows that 221 patients are
taken evoheller it include both inpatients and out patients  from this 103 patients are
taken the evoheller in the range of 201-300  and it is 22.3 %of total study population
In this study I collect total medical cost range of each and every patient in
my study ,out of 462 patients 170 patients have more than 1201 cost range ,and all
those patients are out patients .in case of out patients ,116 patients medical cost is in
average 601-800 its around 25.1% of total patients.
In this theses’ work I collected non medical cost of the patient it shows that
201-400 cost range of patients are 131, 401-600 range patients are 160 its around
34.6%and 1001 or more range are 170 it s around 36.7%  over all patients all the
170 patients are in patients.
For understanding total cost of prescription I combined with total medical
cost and non medical cost, it shows that 47% of patients are come in the range of
1001-2000, all this patients are out patients and in case of in patients 56% of patients
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are the cost range of 10001 and above. All the inpatients range is started from 4001-
10001 and above,but in case of in patient range is 1-1000 to 3000.
For this study I collected number of days of prescriptions details of all the
patients. The number of days will vary from severity of patients. It shows that 418
patents are in the range of 10-12 days of prescription, it means 90.5% of my study
populations patients are in the range of 10-12 days range.
Average cost of each prescription was find out in the study it shows that  167
patients have the range 100-199 and 125 patients have the range from 0-99,its comes
around the percentage 36.2 and 27.1 respectively and all the above mentioned is out
patients details only. In case of in patients ranges from 400-499 to 1000 and above,in
this 38 patients are range from 900-999.
Finally  I  collected  different  type  of  antibiotics  used  for  pneumonia,
antibiotics are prescribed according to patients diseases condition. From my study
16  different antibiotics are prescribed .and my study shows that Azithromycin was
more prescribed that  is  204 antibiotic prescriptions .and then the combination of
amoxicillin with pottasium clavulanate is around 92 prescriptions. The study shows
that out of 462 pneumonia patients 744 antibiotics are prescribed, that is both in the
form of orals and injections.
I conclude the study, Antibacterial prescription trend in bronchopneumonia,
cost of antimicrobial prescription in bronchopneumonia and total treatment cost of
bronchopneumonia  was  understood  and  Medical  cost  involved  in  treating
bronchopneumonia and non medical  cost  involved in treating bronchopneumonia
was studied.
Dept.of pharmacy practice 36 JKKMMRF College of pharmacy
Chapter 1 Introduction
Economies is  about trade-offs and choices between wants,  needs,  and the
scarcity  of  resources  to  fulfill  these  wants.  When  considering  economies,  most
people think of the trade-offs between goods and services and money; however the
trade-off might also be expressed in humanistic terms. We are therefore, careful to
include  both  resource  use  and  humanistic  evaluations  of  drug  therapy  within
Pharmacoeconomics assessment.
used in the model come from 
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LITERATURE REVIEW
Jarab A.S et.  al.,(  2011) has  evaluate the impact  of pharmaceutical  care
intervention, with a strong focus on self- management, on a range of clinical and
humanistic outcomes in patients with Bronchopneumonia. Total of 133 pneumonia
patients  were  randomly  assigned  to  intervention  or  control  group.  A structured
education  about  pneumonia  and  COPD  and  management  of  its  symptoms  was
delivered by the clinical pharmacist for patients in the intervention group. Patients
were followed up a scheduled visit. Effectiveness of the intervention was assessed in
terms of improvement in health-related quality of life medication adherence, disease
knowledge and healthcare utilization. Data collected at baseline and at assessment
was  coded  and  entered  into  SPSS  total  of  66  patients  were  randomized  to  the
intervention group and 67 patients were randomized to the control group. Although
the current study failed to illustrate significant improvement in health-related quality
of  life  parameters,  the  results  indicated  significant  improvements  in  pneumonia
knowledge the enhanced patient  outcomes as a result  of the pharmaceutical care
programmers  in the present  study demonstrate  the value of  an enhanced clinical
pharmacy  service  in  achieving  the  desired  health  outcomes  for  patients  with
pneumonia and COPD
Samiar S.Shah,et al.,1994-2007 conducted a study about Ambulatory Visit
Rates  and  Antibiotic  Prescribing  for  Children  with  Pneumonia,   Department  of
Pediatrics,  University  of  California,  San  Francisco,  California  declined  after  the
widespread use of the heptavalent pneumococcal conjugate vaccine.  The national
incidence of outpatient visits for CAP, however, is not well established. Although no
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pediatric  CAP treatment  guidelines  are  available,  current  data  support  narrow-
spectrum antibiotics as the first-line treatment for most patients with 
Moller  AH,et  al.,in  the  year  of 2012   conducted  a  study  on  cost-
effectiveness analysis of reducing ventilator-associated pneumonia   at a Danish ICU
with ventilator bundle More than 100,000 patients each year in Denmark experience
nosocomial infections, erroneous medication, or pressure ulcers while hospitalized.
The Danish Safer Hospital Program includes 12 bundles for improving patient safety
through the introduction and maintenance of evidence-based routine treatment  or
standard  procedures.  For  the  study  I  have  collected  462  bronchopneumonia
prescription, and dates from two hospitals.After collecting prescription to check the
prescription  according  to  standard  guideline.   From the  prescription  I  separated
patents demographics data such as gander wise distribution, alcoholic distribution,
smoking wise distribution ,age wise distribution ,hospital wise distribution and anti
microbial  prescription wise  distribution  data’s.  From the  prescription  I  collected
patients medical cost, and separately oral cost injections rate, evoheller cost and total
medical cost. Also collected non medical cost such as laboratory tests cost ,nursing
cost ,travelling cost  ,in case of inpatient I collected hospital room cost  also then
prepared non medical cost of each and every patients and recorded it .I collected
total  medical cost of bronchopneumonia from additions of both medical and non
medical cost. Bronchopneumonia is one the infectious disease and I find number of
days of medical treatement, and average of prescription per day. Finally differentiate
type of antibiotics prescribed for the patient’s ant its total.
Dept.of pharmacy practice 39 JKKMMRF College of pharmacy
Chapter 2 Literature Review
The cost per VAP episode prevented was 311570rupees, and cost per death
prevented  was  2225440rupees.  The  incremental  cost-effectiveness  scatter  plot
showed that VB was more effective in 99.9%, and 42.6% have lower cost and better
outcome  for  prevention  of  VAP.  The  incremental  cost-effectiveness  scatter  plot
showed that VB was more effective in 85.9%, and 31.6% have lower cost and better
outcome for death prevented    
Monique  Martin,et  al.,2008was  conducted  a  study on  cost-effectiveness
analysis of antimicrobial treatment of community-acquired pneumonia taking into
account  resistance  in  Belgium  .  Research  Centre  for  Pharmaceutical  Care  and
Pharmaco-economics,  Katholieke  Universities  Leuven,  Belgium  This  article
assesses the cost-effectiveness of outpatient antimicrobial treatment of community-
acquired pneumonia (CAP) taking into account resistance in Belgium. there decision
analytic model focused on mild to moderate CAP, but did not consider severe CAP.
Treatment pathways reflected empirical treatment initiated in the absence of data on
CAP  etiology.  First-line  treatment  consisted  of  moxifloxacin,  co-amoxiclav,
Cefuroxime or clarithromycin. If first-line treatment was unsuccessful, patients were
either  hospitalized  or  second-line  treatment  with  a  different  antimicrobial  was
initiated. Clinical failure rates were obtained from the published literature or expert
opinion. Costs were calculated using published sources from the third-party payer
perspective. Effectiveness  measures  included  first-line  clinical  failure  avoided,
second-line  treatment  avoided,  hospitalization  avoided  and  death  avoided.
Healthcare costs were included, but costs of productivity loss were not considered.
Costs  of  treating  a  CAP  episode  amounted  to  10080  with  moxifloxacin/co-
amoxiclav;  15540  with  co-amoxiclav/clarithromycin;  14770  with  Cefuroxime
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/moxifloxacin; and 13510 with clarithromycin/moxifloxacin. The rate of first-line
failure was 5%, 16%, 19% and 18% for these four treatment strategies, respectively.
The  rate  of  second-line  treatment  amounted  to  4%,  13%,  16%  and  15%,
respectively. The hospitalization rate was 1%, 4%, 4% and 4%, respectively.  The
death rate was 0.01%, 0.04%, 0.03% and 0.03%, respectively. Sensitivity analyses
supported the dominance of co-amoxiclav/ moxifloxacin in nearly all scenarios
De Pas cale G, et al.,In the year of 2006 Carried out a study on Steroids in
severe pneumonia.  He Despite more than sixty years of scientific medical research
in  USA  about  severe  pneumonia,  For  the  study  I  have  collected  462
bronchopneumonia  prescription,  and  dates  from  two  hospitals.After  collecting
prescription to check the prescription according to standard guideline.   From the
prescription I separated patents demographics data such as gander wise distribution,
alcoholic distribution, smoking wise distribution ,age wise distribution ,hospital wise
distribution  and  anti  microbial  prescription  wise  distribution  data’s.  From  the
prescription I collected patients medical cost, and separately oral cost injections rate,
evoheller  cost  and  total  medical  cost.  Also  collected  non  medical  cost  such  as
laboratory tests cost ,nursing cost ,travelling cost  ,in case of inpatient I collected
hospital room cost also then prepared non medical cost of each and every patients
and recorded it .I collected total medical cost of bronchopneumonia from additions
of  both  medical  and  non medical  cost.  Bronchopneumonia  is  one  the  infectious
disease and I find number of days of medical treatement, and average of prescription
per day. Finally differentiate type of antibiotics prescribed for the patient’s ant its
total.
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either community-acquired or bronchopneumonia, remains a leading cause of death
regardless of the patients' immunity state. The clinical introduction of new and more
potent antibiotic molecules and the continuous development of efficientrespiratory
assistance   devices may not be able to radically improve the clinical outcome of
pneumonia. Adjunctive therapies based on the physio pathological mechanisms of
lung  damage  in  severe  pneumonia  have  been  strongly  advocated,  and
corticosteroids, which present many properties that theoretically interfere with these
pathways, have been widely used, with conflicting results. The aim of this review is
to examine existing literature data on steroid use in severe pneumonia
Michiel B.heeseker, et al.,in the year between of 2000to 2009 was conduct a
study  of  Trends  in  Antibiotic  Prescribing  in  Adults  in  Dutch  General  Practice
.Antibiotic  consumption  is  associated  with  adverse  drug  events  (ADE)  and
increasing  antibiotic  resistance.  Detailed  information  of  antibiotic  prescribing  in
different age categories is scarce, but necessary to develop strategies for prudent
antibiotic use. The aim of this study was to determine the antibiotic prescriptions of
different antibiotic classes in general practice in relation to age. Retrospective study
of 22 rural and urban general practices from the Dutch Registration Network Family
Practices (RNH). Antibiotic prescribing data were extracted from the RNH database
from 2000–2009. Trends over time in antibiotic prescriptions were assessed with
multivariate  logistic  regression  including  interaction  terms  with  age.  Registered
ADEs as  a  result  of  antibiotic  prescriptions  were  also  analyzed.In  total  658,940
patients years were analyzed. In 11.5% (n = 75,796) of the patient years at least one
antibiotic was prescribed. Antibiotic prescriptions increased for all age categories
during  2000–2009,  but  the  increase  in  elderly  patients  (>80  years)  was  most
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prominent.  In  2000  9%  of  the  patients  >80  years  was  prescribed  at  least  one
antibiotic  to  22%  in  2009  (P<0.001).  Elderly  patients  had  more  ADEs  with
antibiotics and co-medication was identified as the only independent determinant for
ADEs.
Postma  DF, van  Werkhoven et.al.,  In the year of2010  Was study New
trends  in  the  prevention  and  management  of  community-acquired  pneumonia
.Community-acquired  pneumonia  (CAP)  is  an  important  cause  of  morbidity and
mortality worldwide. This review summarizes current trends and knowledge gaps in
CAP  management  and  prevention. For  the  study  I  have  collected  462
bronchopneumonia  prescription,  and  dates  from  two  hospitals.After  collecting
prescription to check the prescription according to standard guideline.   From the
prescription I separated patents demographics data such as gander wise distribution,
alcoholic distribution, smoking wise distribution ,age wise distribution ,hospital wise
distribution  and  anti  microbial  prescription  wise  distribution  data’s.  From  the
prescription I collected patients medical cost, and separately oral cost injections rate,
evoheller  cost  and  total  medical  cost.  Also  collected  non  medical  cost  such  as
laboratory tests cost ,nursing cost ,travelling cost  ,in case of inpatient I collected
hospital room cost also then prepared non medical cost of each and every patients
and recorded it .I collected total medical cost of bronchopneumonia from additions
of  both  medical  and  non medical  cost.  Bronchopneumonia  is  one  the  infectious
disease and I find number of days of medical treatement, and average of prescription
per day. Finally differentiate type of antibiotics prescribed for the patient’s ant its
total.
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 Although  Streptococcus  pneumoniae  is  the  most  frequent  cause  of  CAP,
identification  of  the  microbial  cause  of  infection  remains  unsuccessful  in  most
episodes and little is known about the aetiology of CAP in immunocompromised
patients. Urinary antigen testing has become standard care for diagnosing Legionella
infection,  and pneumococcal  urinary antigen testing is  now recommended in  the
Dutch guidelines to streamline antibiotic therapy in patients hospitalized with CAP.
In  primary  care  C-reactive  protein  determination  is  recommended  to  improve
antibiotic prescription for lower respiratory tract infections. In patients hospitalized
with CAP, three strategies are considered equally effective for choosing empirical
antibiotic treatment. Yet, more (and better designed) studies are needed to determine
the  best  strategy,  as  well  as  to  determine  optimal  (which  usually  means  the
minimum) duration of antibiotic  therapy and the role of adjuvant treatment  with
corticosteroids.  The  effectiveness  of  the  23-valent  pneumococcal  polysaccharide
vaccine  in  preventing  invasive  pneumococcal  disease  and  pneumococcal  CAP
remains  debated,  and  whether  the  newer  conjugate  vaccines  are  more  effective
remains to be determined. Many of these questions are currently being addressed in
large-scaled trials in the Netherlands, and their results may allow evidence-based
decisions in CAP management and prevention.
Mats Arne et. al.,  2011was conducted a study on cost effective analysis of
pneumonia  and  COPD  To  gain  a  more  positive  outlook  on  the  disease,sample
collected from the random population in Sweden in 2004 and 2008. The prevalence
of subjects (40–84 years) who reported having pneumonia was 2.1% in 2004 and
2.7% in 2008. Data were analyzed for 1475 subjects. Regression models were used
to  analyze  the  associations  between  health  measures  most  important  factor
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associated  with  good,  self-rated  health  and  quality of  life  was  level  of  physical
activity. Odds ratios for general health varied from 2.4 to 7.7 depending on degree of
physical activity, where subjects with the highest physical activity level reported the
best health and also highest quality of life
P.J. Wijkstra et. al., 1994 they had  developed a rehabilitation programme at
home and have investigated its effects on quality of life (QOL), lung function, and
exercise tolerance in patients with Pneumonia and chronic obstructive pulmonary
disease  (COPD).  We studied  43  patients  with  severe  airflow obstruction:  forced
expiratory volume in one second (FEV1) 1.3±0.4 l FEV1/inspiratory vital capacity
(IVC) 37±7.9%. After stratification, 28 patients were randomly allocated in a home
rehabilitation program for 2 weeks. Fifteen patients in a control group received no
rehabilitation.  The  rehabilitation  group  received  physiotherapy  by  the  local
physiotherapist, and supervision by a nurse and a general practitioner. 
Quality  of  life  was  assessed  by  the  four  dimensions  of  the  Chronic
Respiratory Questionnaire they found a highly in significant improvement in  the
rehabilitation group compared to the control  group for  the dimensions dyspnoea,
emotion, and mastery. Lung function showed no changes in the rehabilitation group.
The exercise tolerance improved significantly in the rehabilitation group compared
to the control group. The improvement in quality of life was not correlated with the
improvement in exercise tolerance. Rehabilitation of pneumonia and COPD patients
at home may improve quality of life; this improvement is not correlated with an
improvement in lung function and exercise tolerance.
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AIM AND OBJECTIVE
AIM
To understand   the cost of bronchopneumonia treatment at a tertiary care
hospital in both IN and OUT patients
OBJECTIVES
 To understand the antibacterial  prescription  trend in bronchopneumonia
 Understand  the cost of  antibacterial prescription in bronchopneumonia 
 Study the medical cost involved in treating bronchopneumonia 
 Study the non medical cost involved in treating  bronchopneumonia
 To understand the total treatment  cost of  bronchopneumonia
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PLAN OF WORK
The present dissertation work was planned in 4 phases
PHASE 1
 Initial study to identify the scope of work
 Literature survey
 Preparation of study protocol
PHASE 2
 I E C clearance 
 Designing of data entry format
 Gaining consent from hospital authority and patients
 Data collection
PHASE  3
 Identification of Pattern of drug use
PHASE 4
 Analysis of data
SOURCE OF DATA:
 From doctors prescription
 Hospital records
 Patient interviews
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METHODOLOGY
This chapter discuss about study site, study population, study design, data
collection and data analysis.
STUDY SITE
Study is carried out in two hospitals of malappuram and palakkad districts in
kerala.Shankerhospital  cherpulassery  andRamdas  clinic  and  nursing  home
perinthalmanna.Both hospitals having more than 100 beds specialized in most of
various department like pediatrics,general medicine, ophthalmology, gynecology,etc.
STUDY DESIGN
A observational study to evaluate antimicrobial prescription trend and direct
cost analysis of various drug prescribed for bronchopneumonia.
SAMPLE SIZE
462 prescriptions from pneumonia patients.
STUDY PREIOD  
May 2013 to February 2014 (10 months)
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STUDY CRITERIA:
INCLUSION CRITERIA
• Patients above the age of 10
• Patients below the age of 65
• Patients suffering from pneumonia
EXCLUTION CRITERIA
• Patients above the age of 65
• Mentally retarded patients
• Patients who have multiple illness 
• Pregnant and lactating women’s  
• Non consultation patients
• An individual who use multiple care providers
STUDY PROCEDURE
For the study I have collected 462 bronchopneumonia prescription, and dates
from two hospitals.After collecting prescription to check the prescription according
to standard guideline.  From the prescription I separated patents demographics data
such as gander wise distribution, alcoholic distribution, smoking wise distribution
,age wise distribution ,hospital wise distribution and anti microbial prescription wise
distribution  data’s.  From  the  prescription  I  collected  patients  medical  cost,  and
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separately  oral  cost  injections  rate,  evoheller  cost  and  total  medical  cost.  Also
collected  non medical  cost  such as  laboratory tests  cost  ,nursing cost  ,travelling
cost  ,in  case  of  inpatient  I  collected  hospital  room cost  also  then  prepared  non
medical cost of each and every patients and recorded it .I collected total medical cost
of  bronchopneumonia  from  additions  of  both  medical  and  non  medical  cost.
Bronchopneumonia  is  one  the  infectious  disease  and  I  find  number  of  days  of
medical treatement, and average of prescription per day. Finally differentiate type of
antibiotics prescribed for the patient’s ant its total.
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RESULTS AND DISCUSSION
DEMOGRAPHICAL DATA
Bronchopneumonia is the one of the most spreading disease in the world.
Pneumonia is a common illness affecting approximately 450 million people a year
and occurring in all parts of the world. It is a major cause of death among all age
groups resulting in 4 million deaths yearly
The  area  which  I  preferred  for  my  thesis  regarding  my  study
bronchopneumonia  two  hospitals  in  malapuram  and  palakkad  district  in
kerala.Ramdas  hospital  and  poly clinic  perintalmanna  in  malapuram district  and
Shankar hospital cherpulassery in palakkad district
Age wise distribution data
There is no significant relation between age and bronchopneumonia in my
study .The age wise distribution data shows that highest number of patients consults
with physician their age range between 31-40 yrs.
Table 1: Age wise distribution data
Age  range(In yrs) Male Female N=462 (%)  to total
11-20 20 16 36 7.8%
21-30 31 21 52 11.2%
31-40 92 52 144 31.2%
41-50 65 44 112 24.2%
51-60 57 32 89 19.3%
61-70 27 5 29 6.2%
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A total of about 462 patients were selected for this study. The table 1 shows
the demographical  data of the study conducted. It  was noted that out of the 462
patients who part of the study different age group were. The chart clearly describes
about the total number of people who attended the study from different age groups. 
Figure 1: Age wise distribution data
From above graphical picture, we can easily find out the different age group
of patients suffering from bronchopneumonia .The age limit chart says that about
11-20 age  limit’s  around 7.8%,  21-30 age  limit  around 11,2%,  31-40 age limit
around 31.2%,  41-50age limit around 24.2%,  51-60age limit around 19.3%, and
age limit 61-70 around 6.2%.The chart says that the age limit between 31-40shows
that  more  patients  affected  pneumonia  in  study  .It  around  31.2%  total  study
population
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Gender wise distribution data
There is no significant relation between gender and bronchopneumonia in
my study,but in my study shows that male patients are more than female. 
Table 2: Gender wise distribution data
Gender N=462 Percentage to total
Male 292 63%
Female 170 37%
                 A total of about 462 patients completed this study. The table 2 shows the
demographical data of the study conducted. It was noted that out of the 462 patients
who were part of the study 292 were males and 170 were females. The chart clearly
describes about the total number of people who attended the study from different age
groups and the chart also gives a clear cut idea about the number of male and female
patients who attended the program from different age groups and also says about the
percentage  of  males  and  females  from  different  age  groups  who  suffers  from
pneumonia.
FIGURE 2: Gender wise distribution data
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According  to  the  graphical  picture,  male  patients  were  more  affected  to
bronchopneumonia than female patents. The chart says that about 63% of patients
who attended the studies were males and about 37% were females.
Smoking habit data
Bronchopneumonia is a respiratory tract infectious disease mainly affected in
lungs and respiratory tract .Now a days the smoker’s population is increased all over
India. So I collected number of patient are smoker in my study population  
TABLE 3: Smoking habit data
Smoking habit N=462 Percentage to total
Smokers 204 44.2%
Non smokers 258 55.8%
In my theses I have to collect smoking habit of patient’s .The table shows
that  204 patients are smokers  and 258 patients  are non smokers  among the 462
patients.
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FIGURE: 3 smoking habit data
Smoking is the one of the main problem of all respiratory diseases ,smoking
will leads to COPD, breathing difficulties  and more over it  will leads to cancer
From the above figure 3 shows that 44.2% patients are  smokers and 55.8% are non
smokers .It means 258 patients are non smokers and 204 patients are smokers. From
the above figure we can analysis that smokers are easily affect pneumonia than non
smokers
 Alcoholic habit patient data
Now days peoples know the adverse effect alcohol .Then also some peoples
are used alcohol and alcohol containing beverages. 
Table 4: Alcoholic habit patient data
Alcohol habit N=462 Percentage to total
Alcoholic patients 97 21%
Non alcoholic patients 365 79%
In my study I have to collect alcohol   habit of patients .The table shows that
97 patients are alcoholic and 258 patients are non alcoholic among the 462 patients
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Figure 4: Alcoholic habit patient data
From the above figure 4 shows that  21% patients are alcoholic and 79%
patients are non alcoholic from the total of 462 patients
Patient distribution data
Bronchopneumonia  is  a  easily  spreading  diseases  and  without  medical
treatment  it  will  lead  to  death  pneumonia  mainly  affected  in  small  children.
Pneumonia  occurred  in  approximately  156  million  children,  151  million  in  the
developing countries   and 5 million in the developed countries
Table 5 : Patient distribution data
Patent details N=462 Percentage to total
In patient 170 36.8%
Out patient 292 63.2%
In my theses work I collected 462 pneumonia patients’ details. For this study
I  have  to  collect  both  in  patients  and  out  patients.  The  table  5  shows  the
demographical data of the study conducted. It was noted that out of the 462 patients
were part of the study differentiate in inpatients and outpatients
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Figure 5 : Patient distribution data
From the above figure 5 shows that out of 462 patients 292 are out patients
its comes around 63.2%and 170 are in patients and its comes around 36.8%.From
the above figure we can understand that initial stage of pneumonia patients are ready
for treatment then pneumonia is easily curable and avoid hospital admitting .Some
patients are avoid  to consult physician and the disease become chronic then only
they are ready to meet doctors .this condition patients may needs to intravenous
administration of antibiotics .so they must be in hospital as a inpatient
Anti microbial prescription data
Pneumonia is respiratory diseases mainly affected in lungs. So antimicrobial
therapy  is  essential  for  treating  pneumonia,  antimicrobial  agents  will  fight  to
pneumonia causing organisms and easily cure from the infections
Table 6: Anti microbial prescription data
Anti microbial prescription data N=462 Percentage to total
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Number  of  patient  with  antimicrobial
prescription 462 100%
Number of patient without antimicrobial
prescription 0 0
In  this  table shows that  number of  patients  taken antimicrobial  drugs for
bronchopneumonia
Figure 6: Anti microbial prescription data
Bronchopneumonia is a major cause of death among all age groups resulting
in 7% of the world's  total  death rate.  Anti  microbial  therapy is  essential  for  the
treatment for curing the disease .from the above figure 6 shows that  all  the 462
patients got antimicrobial prescription. It means 100% . Most cases of pneumonia
can be treated without hospitalization. Typically,  oral  antibiotics,  rest, fluids, and
home care.
Hospital wise distribution data
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For my theses work I collected data’s from two hospitals Shankar hospital
cherpulassery in palakkad districted ramdas clinic and nursing home perinthalmanna
in malapuram district kerala
Table 7: Hospital  wise distribution data
Name of hospital N=462 Percentage to total
Shanker 267 57.8%
Ramdas 195 42.2%
For my study I  collected  dates  from two hospitals.  A total  of  about  462
patients were selected for this study. The table 7 shows the demographical data of
hospitals. It was noted that out of the 462 patients who were part of the study 267
were from shanker hospital  cherpulasery and 195were  in  the  hospital  of  ramdas
polyclinic and nursing home perinthalmanna
Figure 7: Hospital wise distribution data
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From the above figure shows that 57.8% of patients from Shankar hospital
and 42.2% of patients from Shankar hospital perinthalmanna
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Cost range of antimicrobial prescription
Table 8: Cost range of antimicrobial prescription
Cost range number ofin Patient
number of
out Patient N=462
Percentage
to total
1-200 0 72 72 15.6%
201-400 0 172 172 37.1%
401-600 0 38 38 8.2%
601-800 0 10 10 2.2%
801-1000 0 0 0 0
1001 and
above 170 0 170 36.9%
From the above table different cost range anti microbial prescriptions .the
cost of anti microbial are differ from patients and severity of the disease .and the
cost will wary from in patients and out patients .In case of in patients the cost will
high compare to out patients
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Figure: 8 Cost range of antimicrobial prescription
From the above figure 8 shows that we can easy find out different cost range
and  its  percentage  of  anti  microbial  prescription  for  both  in  patients  and  out
patients  .The  cost  range  from 0-200 of  anti  microbial  prescription  is  around  72
patients  and  the  its  comes  15.6%  of  total  patients.  The  cost  range  from  201-
400antimicrobial prescription is around 172 patients and its comes around 37.2 %of
total patients. the cost range from 401-600 prescription is around 38 patients and the
percentage of total is 8.2.the cost range from 601 -800 antimicrobial prescription is
10 patients and its around 2.2%.the cost range 801-1000are nil .and the cost more
than 1001 is around 170 patients and its comes 36.8% of total bronchopneumonia
patients .From the above figure we can understand that  in patients  antimicrobial
prescription are more costly than out patients prescription.
Total cost range of orals
Table 9:Total cost  range of oral
Range In patient Out patient N=462 Percentage to total
1-200 0 2 2 0.4%
201-400 8 50 58 12.6%
401-600 85 209 294 63.6%
601-800 61 31 92 19.9%
801-1000 16 0 16 3.5%
1001 and above 0 0 0 0%
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From the above table different cost range orals in the prescriptions .the cost
of orals  are differ from patients to patients and severity of the disease .and the cost
will wary from in patients and out patients and duration of treatment  
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Figure 9: Total cost range of orals
From the above figure 9 we can easy find out different cost range and its
percentage of oral prescription for both in patients and out patients .The cost range
from 0-200 of orals prescription is around 2 patients and that  its comes 0.4% of
total patients. The cost range from 201-400 of orals is 58 patients and that is comes
12.5% of total patients. The range from 401-600 of orals is 294 patients and that is
comes 63.3 % of total patients. The range from 601 to 800 of orals is 92 patients and
that is comes 19.9% of total patients. The range from 801 to 1000 of orals is 16
patients and that is comes 3.5% of total patients. More than 1001 range oral usage
prescription is nil. From the above figure we can find out 401-600 range patients are
taking orals than all other range
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Total cost range of injections
In  case  of  bronchopneumonia  patients  injections  are  prescribed  for  all
Inpatients because antibiotics are administered through intravenous administration 
Table 10: Total cost range of injections
Total Cost
Range
In
patien
t
Out
patients N=462 Percentage to total
0-1000 0 0 0 0
1001-2000 2 0 2 1.2%
2001-3000 85 0 85 50%
3001-4000 25 0 25 14.7%
4001-5000 41 0 41 24.1%
5001-6000 0 0 0 0
6001-7000 0 0 0 0
7001-8000 16 0 16 9.4%
8001-9000 1 0 1 0.6%
9001-10000 0 0 0 0
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From the above table different cost range injections in the prescriptions .the
cost of injections are differ from patients to patients and severity of the disease.
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Figure 10: Total cost range of injections
From the above figure 10 shows that we can easy find out different  cost
range  and  its  percentage  of  injections  .The  figure  shows  that  injections  are
prescribed only for inpatient not prescribed for outpatients   .The cost range from 0-
1000 of injections prescription is zero. The cost range from 1001-2000 injections is
around 2 patients and its comes around 0.3 %of total patients. the cost range from
2001-3000  prescription  is  around  85  patients  and  the  percentage  of  total
is18.5%.The cost range from 3001 -4000 injections in the prescription is 25 patients
and  its  around  5.4%.the  cost  range  4001-5000  injections  in  the  prescriptions
is41patients  and  its  around   8.9% .The  cost  range  from5001-6000  of  injections
prescribed for the patients  is zero . The cost range from6001-7000 of injections
Dept.of pharmacy practice 63 JKKMMRF College of pharmacy
Chapter 6 Results and Discussion
prescribed  for  the  patients   is  zero  .The  cost  range  from  7001-8000  injections
prescribed for the pneumonia patients  is around 16 patients and its comes around
3.5  %of  total  patients.  the  cost  range  from 8001-9000  prescription  is  around  1
patients  and  the  percentage  of  total  is0.2%.The  cost  range  from  9001  -10000
injections for the patients is zero.  From the above figure we can easily find out
2001-3000 range of injections are prescribed more compare to other range.
Total cost range of other route(Evoheller)
Now a day’s evoheller are prescribed for respiratory tract infectious disease
like pneumonia and COPD. Commonly used evoheller are corticosteroids ,in the
tablet or oral dosage form it will shows more adverse drug reactions .To overcome
this unwanted reactions they are prescribed in the form of evoheller.
Table11: Total cost range of other route (evoheller)
Total cost
range In patient Out patient N=462
Percentage to
total
0-100 0 6 6 1.3%
101-200 0 0 0 0%
201-300 60 43 103 22.3%
301-400 8 2 10 2.2%
401-500 72 30 102 22.1%
501-600 0 0 0 0
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Bronchopneumonia is affected in lungs so that respiration difficult may be
occur in most of the patients .Doctors are prescribed evoheller along with antibiotics
and orals .The above table 11 shows thevohaller usages
Figure 11: total cost range of other route
The above figure 11 shows the cost range of evoheller and from above figure
we can easily find out different cost range and number of prescription in each range
and its percentages 
The cost range from 0-100 shows that 6 patients and its comes around 2.7
percentage of total  prescriptions.  The cost  range from 101-200 is  zero.  The cost
range from 201-300is 103 and the percentage of total is 22.3. The cost range from
301-400  shows  that  10  patients  and  its  comes  around  2.2  percentage  of  total
prescriptions. The cost range from401-500 shows that 102 patients and it’s comes
around 22.1 percentage of total prescriptions. The cost range from 501-600 is zero.
From the above figure we can easily find out that total number of inpatients used
Dept.of pharmacy practice 65 JKKMMRF College of pharmacy
Chapter 6 Results and Discussion
evoheller are 140 and out patients taken evoheller are 81 total number of patients
taken evoheller are 221 .48%of patients taken evoheller out of 462 patients
Total medical cost range
Table 12: Total medical cost range
Total Medical
cost range In patient
Out
patients N=462
Percentage to
total
0-200 0 0 0 0
201-400 0 32 32 6.9%
401-600 0 79 79 17%
601-800 0 116 116 25.1%
801-1000 0 32 32 6.9%
1001-1200 0 33 33 7.3%
1201 and above 170 0 170 36.8%
From the above table mentioned total medical cost for both in patients and
out patients and over all percentages of all 462 patients
Dept.of pharmacy practice 66 JKKMMRF College of pharmacy
Chapter 6 Results and Discussion
Figure 12: Total medical cost
The above figure 12 shows the  total medical cost and from above figure we
can easily find out different cost range and number of prescription in each range and
its percentages The  medical cost range from 0-200 shows nil .The cost range from
201-400  is 32patients and its comes around 6.9%of over all patients. The cost range
from 401-600is 79 and the percentage of total is 17.1. The cost range from 601-800
shows that 116 patients and its comes around 25.1percentage of total prescriptions.
The cost range from 801-1000 is 32patients and its comes around 6.9%of over all
patients. the cost range from 1001-1200is 33 and the percentage of total is 7.1. All
the above mentioned patients are out patients. The cost range from1 201 and above
is 170patients and its comes around 36.8%of over all patients. From this figure we
can understand that in patients have more medical cost than out patients. All the in
patients medical cost is more than the last range that is 1201 and above.
Total non medical cost
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Table 13: Total non medical cost
Range Inpatients
Out
patients N=462
Percentage to
total
1-200 0 0 0 0
201-400 0 131 131 28.5%
401-600 0 160 160 34.6%
601-800 0 1 1 0.2%
801-1000 0 0 0 0
1001 or
above 170 0 170 36.7%
From the above table mentioned total non medical cost for both in patients
and out patients and over all percentages of all 462 patients 
Figure 13: Total non medical cost
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The above figure 13 shows the  total non  medical cost and  we can easily
find  out  different  cost  range  and  number  of  prescription  in  each  range  and  its
percentages The  non medical cost range from 1-200 shows nil .The cost range from
201-400  is131patients and its  comes  around 28.5%of over  all  patients.  the cost
range from 401-600is 160  and the percentage of total is 34.6. The cost range from
601-800  shows  that  1  patient  and  itscomes  around  0.2percentage  of  total
prescriptions.  The  cost  range  from  801-1000  is  zero.  All  the  above  mentioned
patients are out patients. The cost range from1 001 and above is 170patients and its
comes around 36.8%of over all patients. From this figure we can understand that in
patients has more non medical cost than out patients. All the in patients non medical
cost is more than the last range that is 1201 and above.
Total cost range
Table 14: Total cost range ( Medical + Non medical)
Total Cost
range
In
patient
Out
patient N=462
Percentage to
total
1-1000 0 73 73 15.8%
1001-2000 0 217 217 47.0%
2001-3000 0 2 2 0.4%
3001-4000 0 0 0 0%
4001-5000 2 0 2 0.4%
5001-6000 28 0 28 6%
6001-7000 29 0 29 6.2%
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7001-8000 6 0 6 1.3%
8001-9000 20 0 20 4.3%
9001-10000 29 0 29 6.3%
10001 and
above 56 0 56 12.1%
Total 170 292 462 100%
From the above table 14 mentioned total cost it means medical +non medical
cost for both in patients and out patients and over all percentages of all 462 patients 
Figure 14: Total cost range
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From the above figure 14 we can identified total cost of a patients including
medical  and  non  medical  cost  .non  medical  cost  including  lab  testing,  x-ray
investigation  reports  ,traveling  expenses,  in  case  of  in  patients  room  rent  also
included in  this  ,doctor  fee,  food expenses  and  other  expenses  .From the above
figure we can find out different range of expenses and number of patients in each
group.
The total  cost  range from 1-1000 shows 73patients and its comes around
15.8% .The cost range from 1001-2000 is217patients and its comes around 47% of
overall patients. the cost range from 2001-3000is 2  and the percentage of total is
0.4%.All this three ranges are only out patients . The cost range from 3001-4000 is
nil.  The  cost  range  from4001-5000 shows that  2  patient  and   its  comes  around
0.4percentage  of  total  prescriptions.  The  cost  range  from  5001-6000  is  28
pneumonia patients and it comes around 6%of total. The cost range from 6001-7000
is 29 patients and its comes around 6.2%of over all patients. The cost range from
7001-8000is 6 and the percentage of total is 1.3%. The cost range from 8001-9000 is
20 patients and its comes around 4.3%of over all patients. the cost range from 9001-
10000is 29 and the percentage of total is 6.3%. The cost range from10001 and above
is 56patients and the percentage of total is 12.1%The above seven ranges shows only
in patients and not out patients .so we can find out that in patients have more total
expenses compare to out patients.
Prescription days range
If  the patients start  medication at  initial  stage and physician find out the
actual disease condition of the disease  then the duration of medication is may be
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little 5 to 7 days, but most of the patients are not care about health .Depending up on
the severity of patient disease condition the number of prescription days will be vary
Table 15: Prescription days range
Days range N=462 Percentage to total
0-3 0 0
4-6 4 0.9%
7-9 38 8.2%
10-12 418 90.5%
12-15 2 0.4%
16 or above 0 0%
From the above table 15 shows that number of days prescribed the medicine
for pneumonia patients. The days will be change the severity of pneumonia 
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Figure 15: Prescription days range
From the above figure we can easily find out the prescription days range of
all the patients and number of range of all the patients and percentage of each range.
The range from 0-3 shows zero priscription,4-6 shows 4patients prescription and its
comes around  0.9%, the range from 7-9 shows 38 patients and its comes around
8.2%,  the range from 10-12 shows 418 patients and its comes around  90.5%, the
range from 13-15 shows 2 patients and its comes around 0.4%,and more than 16
days  prescription  zero.  From  this  figure  we  can  understand  10-12  days  of
prescription is more than all other range
Total treatment cost per day
The average cost of bronchopneumonia treatment is varying from patient to
patient. Treatment duration also vary from severity of disease. In case of inpatients
they have more treatment expenses than out patients; intravenous drugs are more
expensive than orals.
Table 16: Total treatment cost per day
Cost range/day N=462 Percentage to total
0-99 125 27.1%
100-199 167 36.2%
200-299 0 0
300-399 0 0
400-499 27 5.8%
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500-599 33 7.2%
600-699 11 2.4%
700-799 35 7.6%
800-899 14 3%
900-999 38 8.1%
1000 and above 12 2.6%
From the  above table  16  shows  the  average  cost  per  day for  pneumonia
patients. The cost will be change the severity of pneumonia,  and type of patient
details it means in patients and out patients
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Figure 16: Total treatment cost per day
The  above  figure  shows  that  different  cost  range  per  day  of  all
bronchopneumonia  patients  the  ranges  are  vary  from  patient  to  patients  and
severalty of patients.  the  range from 0-99 is  125 patients and its  comes around
27.1%, the  range from 100-199 is 167 patients and its comes around 36.2%, the
range from 200-299 is zero ,the range from 300-399 is also zero, the  range from
400-499 is 27 patients and its comes around 5.8%, the  range from 500-599 is 33
patients and its comes around 7.2%, the  range from 600-699 is 11 patients and its
comes around 2.4%, the  range from 700-799 is 35 patients and its comes around
7.6%, the  range from 800-899 is 14 patients and its comes around 3%, the  range
from 900-999 is 38 patients and its comes around 8.2% and the range more than
1000 is 12 and its percentage is 2.6% ,from this we can find out that in patients have
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more prescription cost than out patient  per days prescription, because in patients
should pay the hospital room rent and laboratory tests 
Anti microbial drugs prescribed in various prescription
Bronchopneumonia is  the one of the major cause of death among all  age
groups resulting in 4 million death yearly. Rates are higher in children less than five,
and adults older than 75 years Antibiotics for bronchopneumonia include third- and
fourth-generation  cephalosporins,  carbapenems,  fluoroquinolones,  amino
glycosides,  and  vancomycin.  These  antibiotics  are  usually  givenaoral  and
intravenously.  Multiple  antibiotics  may  be  administered  in  combination  in  an
attempt to treat all of the possible causative microorganisms. Antibiotic choices vary
from hospital to hospital and patient to patients because of regional differences in
the most likely microorganisms, and because of differences in the microorganisms'
abilities to resist various antibiotic treatments
Antibiotic treatment is essential for the for pneumonia otherwise it will leads
to chronic obstructive pulmonary disease and will leads to death
Physicians prescribe antibiotics for pneumonia depending up on the severity
and also patient body nature  
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Table 17:Anti microbial drugs  prescribed in various prescription
Antimicrobial drugs
Route
N=462 Percentage to
totalOra
l Injections
Procaine penicillin 0 9 9 1.9%
Cefuroxime 0 15 15 3.2%
Ciprofloxacin 16 0 16 3.5%
Amoxicillin 26 0 26 5.6%
Levofloxacin 28 0 28 6%
Cefotaxime 0 47 47 10.2%
Amikacin 0 54 54 11.7%
Cefixime 60 0 60 12.9%
Meropenam 0 60 60 12.9%
Doxycyclin 61 0 61 13.2%
Ceftriaxon+tazobactum 0 71 71 15.4%
Amoxicillin+potasium
clavulanate 92 0 92 19.9%
Azithromycin 160 45 205 44.4%
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The above table shows that different antimicrobials prescription in each and
every  patients.  This  also  shows  the  route  of  anti  microbial  prescriptions  for
pneumonia patients 
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Figure 17: Antimicrobial drugs prescribed in various prescriptions
From the above figure 17 shows that all the anti microbial prescribed for
bronchopneumonia  patients,  route  and  number  of  antimicrobials  in  each
prescription. The figure shows that procaine penicillin  is prescribed for 9 patients in
intra  venous  route  of  administration  this  is  around  1.9%  of  total  prescription.
Cefuroxime is prescribed for 15 patients in intra venous route of administration this
is around 3.2% of total prescription, Ciprofloxacin is prescribed in 16  prescription
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in oral route this is 3.5 percentage of total prescription, amoxicillin is prescribed in
26 prescription in oral route this is 5.6 percentage of total prescription ,Levofloxacin
is  prescribed  in  28  prescription  in  oral  route  this  is  6.0  percentage  of  total
prescription,  Cefotaxime  is  prescribed  for  47  patients  in  intra  venous  route  of
administration this is around 10.1% of total prescription, .   Amikacin is prescribed
for 54 patients in intra venous route of administration this is around 11.7% of total
prescription,  Cefixime is  prescribed in  60  prescription in oral  route this  is  12.9
percentage of total prescription , Meropenam is prescribed for 60 patients in intra
venous  route  of  administration  this  is  around  12.9%  of  total  prescription  ,
Doxycyclin is prescribed in 61  prescription in oral route this is 13.2 percentage of
total  prescription,  Ceftriaxon  and  tazobactum  combination   is  prescribed  in  71
prescription  in  intra  venous  route  this  is  15.4  percentage  of  total  prescription,
Amoxicillin and potassium clavulanate combination is prescribed in 92patients this
19.9%of overall prescription, Azithromycin is prescribed for 205 patients in both
oral  and  intra  venous  route  of  administration  this  is  around  44.4%  of  total
prescription,
From this study I find out that Azithromycin is more prescribed antibiotic
and procaine penicillin is less prescribed antibiotics for bronchopneumonia in my
study.
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CONCLUSION
This observational study is “to evaluate antimicrobial prescription trend and
direct cost analysis of various drug prescribed for bronchopneumonia”, the study
concludes that patients age wise demographic data shows that 31.2% patients are in
the age group of 31-40 out of  462 patient  144 patients are the above age group
.Gender wise demographic data shows that 292 pneumonia patients are male and
a170 patients are females in my study. Smoking habit distribution data shows that
204 patients are smoker its comes around 44.2% total study population .smokers are
easily  affect  pneumonia  according  to  standard   guidelines   .Anti  microbial
prescription  data  shows  that  100%  patients  are  got  antimicrobial  prescription
because   pneumonia  totally  recovered  from  the  patient   body   by  the  use  of
antimicrobial  administration  .  For  the  theses  work  I  collected  details  from  two
hospitals,  it  shows  267  patients  from   shanker  hospital  and  195  patients  from
ramdas hospital
Cost range of antimicrobial prescription is different in each every patient in
my study shows that 36.9 patients have more than 1000 rupees for antibiotics ,and
all this patients are inpatients and 37.1% of patients have anti biotic cost range from
2001-400 all this patients are out patients and its 172 patients
Orals route of drugs such as antibiotics and other oral drugs are  such as
tablets and syrups cost range vary from patient to patients in my study shows that
294  patients  are  in  the  range  of  401-600  cost  range  its  63.6%  of  total  study
population .
Dept.of pharmacy practice 80 JKKMMRF College of pharmacy
Chapter 7 Conclusion
In my study cost range of injections only for out patients not for in patients
because in my study only inpatients are taken injections .it shows that 85 patients are
taken injections in the range of 2001-3000 ,and 25  patients taken in the cost range
of 3001-4000.
Cost range of evoheller is taken in this study it shows that 221 patients are
taken evoheller it include both inpatients and out patients  from this 103 patients are
taken the evoheller in the range of 201-300  and it is 22.3 %of total study population
In this study I collect total medical cost range of each and every patient in
my study ,out of 462 patients 170 patients have more than 1201 cost range ,and all
those patients are out patients .in case of out patients ,116 patients medical cost is in
average 601-800 its around 25.1% of total patients.
In this theses’ work I collected non medical cost of the patient it shows that
201-400 cost range of patients are 131, 401-600 range patients are 160 its around
34.6%and 1001 or more range are 170 it s around 36.7%  over all patients all the
170 patients are in patients.
For understanding total cost of prescription I combined with total medical
cost and non medical cost, it shows that 47% of patients are come in the range of
1001-2000, all this patients are out patients and in case of in patients 56% of patients
are the cost range of 10001 and above. All the inpatients range is started from 4001-
10001 and above,but in case of in patient range is 1-1000 to 3000.
For this study I collected number of days of prescriptions details of all the
patients. The number of days will vary from severity of patients. It shows that 418
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patents are in the range of 10-12 days of prescription, it means 90.5% of my study
populations patients are in the range of 10-12 days range.
Average cost of each prescription was find out in the study it shows that  167
patients have the range 100-199 and 125 patients have the range from 0-99,its comes
around the percentage 36.2 and 27.1 respectively and all the above mentioned is out
patients details only. In case of in patients ranges from 400-499 to 1000 and above,in
this 38 patients are range from 900-999.
Finally  I  collected  different  type  of  antibiotics  used  for  pneumonia,
antibiotics are prescribed according to patients diseases condition. From my study
16  different antibiotics are prescribed .and my study shows that Azithromycin was
more prescribed that  is  204 antibiotic prescriptions .and then the combination of
amoxicillin with pottasium clavulanate is around 92 prescriptions. The study shows
that out of 462 pneumonia patients 744 antibiotics are prescribed, that is both in the
form of orals and injections.
I conclude the study, Antibacterial prescription trend in bronchopneumonia,
cost of antimicrobial prescription in bronchopneumonia and total treatment cost of
bronchopneumonia  was  understood  and  Medical  cost  involved  in  treating
bronchopneumonia and non medical  cost  involved in treating bronchopneumonia
was studied.
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LIMITATIONS OF THE STUDY
Antimicrobial  prescription  trend  and  direct  cost  analysis  of  various  drug
prescribed for bronchopneumonia which is done from valluvandu area in kerala, I
have done this theses in   proper way but some limitation persist there 
Some of the limitations are:
 Number of patients isless, large number of patients arerequired for this study.
 It’s only limited to bronchopneumonia patients.
 This is only a observational study but a detailed study is required.
 Prescription details from the age limit of 10-75 years is collected for this
study,  Pediatric  and  geriatric  patients  apart  from  this  age  range  are  not
included in this study.
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